- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00413764
Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)
February 2, 2022 updated by: Organon and Co
A Multicenter, Randomized, Double-Blind, Double Dummy Trial to Compare the Effects Tibolone and Transdermal Continuous Combined Estradiol/Norethisterone on Sexual Desire and Arousal in Postmenopausal Women With Sexual Dysfunction
Tibolone has been registered for treatment of menopausal symptoms.
It is, however, not known what the effects are of tibolone in postmenopausal women diagnosed with sexual dysfunction.
This is important because there is currently no approved treatment of libido problems in postmenopausal women.
Therefore, the primary aim of this study was to compare the effects of tibolone with an estrogen/progestogen skin patch in postmenopausal women diagnosed sexual dysfunction.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
358
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Physically and mentally healthy postmenopausal women, >=48 and <=68 years of age, with an intact uterus.
- Women were to suffer from decreased satisfactory sexual activity compared to younger age and sexual problems were not to be considered caused by relationship/partner problems. The decreased sexual functioning was to result in sexually related personal distress as confirmed by the FSDS (score =15).
- An affirmative answer was to be given to the following questions: (a) In previous years did you find sexual activity satisfying? (b) Has there been a decline in your satisfaction with sexual activity? (c) Are you satisfied with your partner as a friend?
- All subjects were to have an established sexual relationship of at least 6 months duration prior to screening.
- Women were to be sexually active.
- Normal mammography within 6 months prior to randomization.
- Body mass index >18 and <=32 kg/m2.
- Voluntary written informed consent
Exclusion Criteria:
- Any unexplained abnormal uterine bleeding
- Double layer endometrial thickness >4 mm
- Tibolone or transdermal E2/NETA use within 3 months prior to screening
- Progestogen implants or injections and estrogen/progestogen injectable therapy within 6 months prior to screening
- Use of intra-uterine progestogen
- Unsuccessful previous treatment with androgens or compounds known to enhance androgenic activity
- Current successful treatment with androgens, without applying the applicable washout period of 3 months prior to screening
- Any previous or current unopposed estrogen administration, prior use of estrogen pellets or tamoxifen citrate (previous low dose vaginal estrogen-only applications are allowed)
- Use of anti -androgens within the preceding 5 years prior to screening.
- Women with significant organic disorder of sexual dysfunction or a partner with sexual dysfunction
- Women who had early onset sexual dysfunction (>15 years prior to menopause)
- Women suffering from androgenic alopecia, acne or hirsutism
- Women suffering from illnesses influencing sexuality
- Women using medication influencing sexuality
- Moderate to severe depression
- Current or prior use of antidepressant within 8 weeks prior to screening
- Major gynecological surgery in the preceding 3 months
- Any serious disease or disorder; or any endocrine disorder with systemic disease which would have impaired overall health and well being (controlled hypo/hyperthyroidism and diabetes mellitus Type II was allowed)
- History or presence of severe psychiatric illness and/or any addictions to drugs, medication or alcohol in the past 3 years
- Diseases for which exogenous hormonal steroids were contraindicated.
- History or presence of any malignancy, except successfully treated non-melanoma skin cancers
- History or presence of cardiovascular or cerebrovascular conditions, thrombosis or thromboembolic disorders
- History or presence of liver, gallbladder or renal disease, epilepsy or classical migraine headaches
- Uncontrolled hypertension
- Women with abnormal cervical smear results
- History or presence of breast cancer, suspicious breast lump or mammographic abnormality
- Known hypersensitivity to any of the ingredients of the trial medication.
- Non-compliance with the screening diary
- Current use of raloxifene, clonidine, veralipride, phytoestrogen extracts
- Drugs known to interfere with the pharmacokinetics of the steroids
- Use of investigational drugs within the past 60 days
- Any disease or condition that was clinically relevant and which, in the opinion of the investigator, would have jeopardized the subject's well being during the course of the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
tibolone
|
tibolone (2.5 mg) over 24 weeks
Other Names:
|
Active Comparator: 2
transdermal continuous combined E2-NETA (estradiol-norethisterone)
|
transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare the effect of tibolone (2.5 mg) to transdermal E2/NETA (50/140 mcg) on the vaginal bleeding and spotting rate in healthy postmenopausal women with sexual dysfunction.
Time Frame: Week 13-24 of the in treatment period
|
Week 13-24 of the in treatment period
|
Compare the effect of tibolone to E2/NETA on sexual functioning in healthy postmenopausal women with sexual dysfunction.
Time Frame: Week 8-12 and Week 20-24 of the in-treatment period.
|
Week 8-12 and Week 20-24 of the in-treatment period.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare the effects of tibolone to E2/NETA on the frequency of satisfactory sexual events, the frequency of sexual fantasies and subjective arousal, scores on the FSFI, FSDS, WHQ and endocrine parameters
Time Frame: Week 8-12 and Week 20-24 of the in-treatment period
|
Week 8-12 and Week 20-24 of the in-treatment period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 23, 2004
Primary Completion (Actual)
November 15, 2005
Study Completion (Actual)
November 15, 2005
Study Registration Dates
First Submitted
December 19, 2006
First Submitted That Met QC Criteria
December 19, 2006
First Posted (Estimate)
December 20, 2006
Study Record Updates
Last Update Posted (Actual)
February 4, 2022
Last Update Submitted That Met QC Criteria
February 2, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Antihypertensive Agents
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Estrogens
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Estrogen Receptor Modulators
- Androgen Antagonists
- Anabolic Agents
- Estradiol
- Norethindrone
- Norethindrone Acetate
- Tibolone
Other Study ID Numbers
- P06089
- C-1774
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sexual Dysfunction
-
Istanbul University - Cerrahpasa (IUC)CompletedSexual Dysfunction | Pregnancy Related | Postpartum Sexual DysfunctionTurkey
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompleted
-
Alza Corporation, DE, USACompletedSexual Dysfunction | Erectile Dysfunction | Ejaculation
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedSexual Dysfunction | Erectile DysfunctionFrance, Poland, United States, Belgium, Mexico, Malaysia, Canada, Taiwan, Korea, Republic of, Russian Federation, Argentina, Australia, United Kingdom
-
Royal Holloway UniversityNational Health Service, United KingdomCompletedSexual Dysfunction | Sexual Assault | Sex DisorderUnited Kingdom
-
Man Clinic for Andrology, Male Infertility and...UnknownSexual Dysfunction | Erectile Dysfunction | Premature EjaculationEgypt
-
University of UtahAcerus Pharmaceuticals CorporationWithdrawnSexual Dysfunction | Erectile DysfunctionUnited States
-
Assiut UniversityNot yet recruitingSexual Dysfunction
Clinical Trials on tibolone
-
Organon and CoCompletedPostmenopausal Women
-
The AlfredMonash UniversityUnknownDepression | Major Depressive DisorderAustralia
-
Keogh Institute for Medical ResearchCompletedHDL CholesterolAustralia
-
Organon and CoCompleted
-
Organon and CoCompletedBreast Cancer | Climacteric Symptoms
-
Organon and CoCompleted
-
Peking Union Medical College HospitalNot yet recruitingSleep Disorder | Menopause
-
McGill University Health Centre/Research Institute...Not yet recruitingEndometriosis | FibroidsCanada
-
Schaper & Bruemmer GmbH & Co KGCompleted